CytomX Therapeutics (CTMX) Receivables - Net (2014 - 2026)

CytomX Therapeutics' Receivables - Net history runs 13 years deep, the most recent figure standing at $646000.0 for Q1 2026.

• Quarterly Receivables - Net fell 66.97% year-over-year to $646000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $646000.0 (down 66.97% YoY) and the FY2025 annual result came in at $2.0 million, down 35.13% from the prior year.
• Receivables - Net was $646000.0 for Q1 2026 at CytomX Therapeutics, down from $2.0 million in the prior quarter.
• Across five years, Receivables - Net topped out at $35.0 million in Q4 2022 and bottomed at $646000.0 in Q1 2026.
• A 5-year average of $4.5 million and a median of $2.0 million in 2025 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2022 — Receivables - Net surged 4330.38% — and 2023, when it tumbled 93.71%.
• CytomX Therapeutics' Receivables - Net stood at $35.0 million in 2022, then tumbled by 93.71% to $2.2 million in 2023, then surged by 41.05% to $3.1 million in 2024, then plunged by 35.13% to $2.0 million in 2025, then slumped by 67.91% to $646000.0 in 2026.
• Business Quant data shows CTMX's Receivables - Net at $646000.0 in Q1 2026, $2.0 million in Q4 2025, and $1.6 million in Q3 2025.